CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗二线以上复发/难治性大 B 细胞淋巴瘤的单中心真实世界回顾性研究：鲁汶大学医院五年结果
英文原题：Single center, real-world retrospective study of CAR-T cell therapy for relapsed/refractory large B-cell lymphoma beyond second line: five-year results at the University Hospitals Leuven.
查看英文原题
Single center, real-world retrospective study of CAR-T cell therapy for relapsed/refractory large B-cell lymphoma beyond second line: five-year results at the University Hospitals Leuven.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们的真实世界数据显示缓解率高且持久，与 tisa-cel 相比，axi-cel 在疗效更高、毒性更高方面的趋势不具统计学显著性。
中文摘要
结果
11 例患者（14%）未能接受 CAR-T 输注。在接受输注的患者（n = 68）中，tisa-cel 的最佳总缓解率（ORR）/完全缓解率（CR）为 64%/49%，axi-cel 为 88%/66%（ORR 比较 p = 0.04）。中位随访 13.8 个月后，tisa-cel 组 1 年无进展生存期（PFS）和总生存期（OS）分别为 30% 和 43%，axi-cel 组分别为 48% 和 62%。tisa-cel 后细胞因子释放综合征（CRS）总发生率/3 级发生率为 82%/9%，axi-cel 后为 97%/0%。tisa-cel 后免疫效应细胞相关神经毒性综合征（ICANS）总发生率/3 级发生率为 24%/18%，axi-cel 后为 54%/40%。输注队列非复发死亡率为 13%。
结论
真实世界数据显示两种疗法均有较高且持久的应答，axi-cel 疗效和毒性较 tisa-cel 均较高，但差异趋势未达显著性。结果与其他真实世界登记数据一致，但中位 OS 较短且高级别 ICANS 较多。
展开英文摘要原文
RESULTS
Eleven patients (14%) did not proceed to CAR-T cell infusion. For infused patients ( n = 68), the best overall response rate (ORR)/complete response (CR) rate was 64%/49% for tisa-cel and 88%/66% for axi-cel ( p = 0.04 for ORR). After a median follow-up of 13.8 months, progression-free survival (PFS) and overall survival (OS) at 1 year were 30% and 43% for tisa-cel and 48% and 62% for axi-cel. Cytokine release syndrome (CRS) (all grades/grade 3) occurred in 82%/9% after tisa-cel and in 97%/0% after axi-cel. Immune effector cell-associated neurotoxicity syndrome (ICANS) (all grades/grade 3) occurred in 24%/18% after tisa-cel and in 54%/40% after axi-cel. The non-relapse mortality in the infusion cohort was 13%.
CONCLUSION
Our real-world data show high and durable response rates, with a non-significant trend towards a higher efficacy and higher toxicity for axi-cel compared to tisa-cel. Our results are in line with other real-world registries except for a shorter median OS and more high-grade ICANS.
论文信息
- 作者
- Brijs J、Van Ham J、Dubois B、Sinap F、Vergote V、Dierickx D、Vandenberghe P
- 单位
- Department of Hematology, University Hospitals Leuven, Leuven, Belgium.Belgium
- 期刊
- Acta clinica Belgica2024 Aug
- 原文标识
- PubMed 39415456 · DOI 10.1080/17843286.2024.2399365